Senkyunolide H potentiates bone marrow-derived mesenchymal stem cells therapy for liver cirrhosis by targeting MAEA to enhance ERK-driven HGF secretion

Pharmacological preconditioning of mesenchymal stem cells (MSCs) is a promising strategy to enhance their therapeutic efficacy for end-stage liver disease; however, maximizing this benefit remains a major clinical challenge. Senkyunolide H (SNH), a small-molecule compound derived from Angelica sinen...

Descripción completa

Detalles Bibliográficos

Autores principales:	Yue Liang, Ying-lin Zhang, Tian-yu Cheng, Jia-ying Pu, Zheng Zhang, Gao-feng Chen, Wei Liu, Yong-ping Mu, Jia-mei Chen, Ping Liu
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2026-04-01
Colección:	Pharmacological Research
Materias:	Senkyunolide H Liver cirrhosis Bone marrow-derived mesenchymal stem cells Macrophage erythroblast attacher Hepatocyte growth factor
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S1043661826000757
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!